


I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on January 8, 2009.

TOWNSEND and TOWNSEND and CREW LLP
By: 
Dana Kane

PATENT
Attorney Docket No.: 015280-481100US
Client Ref. No.: E-044-2003/0-US-03
Customer No.: 45115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BERZOSKY and OKAZAKI

Application No.: 10/551,405

Filed: September 29, 2005

For: ENHANCED HIV-1 VACCINES
AND METHODS FOR THEIR USE

Confirmation No. 4476

Examiner: PARKIN, Jeffrey S.

Art Unit: 1648

AMENDMENT

AND

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The following communication is responsive to the Office Action mailed December 10, 2008. Thus, this amendment is timely filed on January 8, 2009. No fee is due.

Further, in response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed December 10, 2008, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing.

Applicants respectfully request reconsideration of the above-referenced patent application in view of the following amendments and remarks.

Appl. No. 10/551,405
Amdt. dated January 8, 2009
Reply to Office Action of December 10, 2008

PATENT

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 4 of this paper.

Remarks/Arguments begin on page 8 of this paper.